Switching Therapy to Fingolimod Improves Clinical and Mri Outcomes

Journal of Neurology, Neurosurgery and Psychiatry - United Kingdom
doi 10.1136/jnnp-2014-309236.147
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Extensive Multiple Sclerosis Reactivation After Switching From Fingolimod to Rituximab

Case Reports in Neurological Medicine
2018English

Predictors for Multiple Sclerosis Relapses After Switching From Natalizumab to Fingolimod

Multiple Sclerosis
Neurology
2014English

Early Antiretroviral Therapy Improves Neurodevelopmental Outcomes in Infants

AIDS
Infectious DiseasesAllergyImmunology
2012English

Doxycycline Improves Clinical Outcomes During Cystic Fibrosis Exacerbations

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2017English

M2 Occlusions as Targets for Endovascular Therapy: Comprehensive Analysis of Diffusion/Perfusion MRI, Angiography, and Clinical Outcomes

Journal of NeuroInterventional Surgery
MedicineSurgeryNeurology
2014English

Comment On: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

Drugs
Pharmacology
2018English

Fingolimod Induces Neurogenesis in Adult Mouse Hippocampus and Improves Contextual Fear Memory

Translational Psychiatry
PsychiatryMolecular NeuroscienceBiological PsychiatryMental HealthCellular
2015English

Ischemic Etiology and Clinical Outcomes Following Cardiac Resynchronization Therapy

Medicina
Medicine
2020English

Switching Maintenance Infliximab Therapy to Biosimilar-Infliximab Does Not Lead to Significant Changes in Health-Related Quality of Life and Clinical Outcomes in Inflammatory Bowel Disease Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy